Titan Spine received 510(k) clearance from the U.S. Food and Drug Administration to commercially release its Endoskeleton TCS.
The interbody fusion device is designed for the cervical spine with integrated fixation. It uses Titan's proprietary surface technology that participates in the fusion process by creating an osteogenic response to the implant's topography.
Paul Slosar, MD, performed the first surgery using the Endoskeleton TCS on Feb. 9 at Saint Francis Memorial Hospital in San Francisco. The device is the 7th interbody device in Titan's portfolio of titanium spinal implant products.
More articles on devices:
7 key trends in joint replacement customization
Amedica files FDA application for spinal implant spacers with porous silicon nitride center — 6 things to know
Revenue up, $147k net loss — 10 key points on RTI Surgical's 2014 financial report